Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma

Michael Gustafson, Yi Lin, Jonathan S. Bleeker, Deepti Warad, Matthew K. Tollefson, Paul L. Crispen, Peggy A. Bulur, Susan M. Harrington, Rebecca R. Laborde, Dennis A. Gastineau, Bradley Leibovich, John Cheville, Eugene D Kwon, Allan B Dietz

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: Immunotherapeutic strategies to treat patients with renal cell carcinoma (RCC) offer new opportunities for disease management. Further improvements to immunotherapy will require additional understanding of the host response to RCC development. Experimental Design: Using a novel approach to understanding the immune status of cancer patients, we previously showed that patients with a certain immune profile had decreased overall survival. Here, we examine in more detail the phenotypic changes in peripheral blood and the potential consequences of these changes in RCC patients. Results: We found that CD14+HLA-DRlo/neg monocytes were the most predominant phenotypic change in peripheral blood of RCC patients, elevated nearly 5-fold above the average levels measured in healthy volunteers. Intratumoral and peritumoral presence of CD14 cells was an independent prognostic factor for decreased survival in a cohort of 375 RCC patients. The amount of peripheral blood CD14+HLA-DRlo/neg monocytes was found to correlate with the intensity ofCD14 staining in tumors, suggesting that the measurement of these cells in blood may be a suitable surrogate for monitoring patient prognosis. The interaction of monocytes and tumor cells triggers changes in both cell types with a loss of HLA-DR expression in monocytes, increases of monocyte survival factors such as GM-CSF in tumors, and increased production of angiogenic factors, including FGF2. Conclusions: Our results suggest a model ofmutually beneficial interactions between tumor cells and monocytes that adversely affect patient outcome. Clin Cancer Res; 21(18); 4224-33.

Original languageEnglish (US)
Pages (from-to)4224-4233
Number of pages10
JournalClinical Cancer Research
Volume21
Issue number18
DOIs
StatePublished - Sep 15 2015

Fingerprint

Renal Cell Carcinoma
Monocytes
Survival
Neoplasms
Blood Cells
Angiogenesis Inducing Agents
Physiologic Monitoring
HLA-DR Antigens
Fibroblast Growth Factor 2
Granulocyte-Macrophage Colony-Stimulating Factor
Disease Management
Immunotherapy
Healthy Volunteers
Research Design
Staining and Labeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. / Gustafson, Michael; Lin, Yi; Bleeker, Jonathan S.; Warad, Deepti; Tollefson, Matthew K.; Crispen, Paul L.; Bulur, Peggy A.; Harrington, Susan M.; Laborde, Rebecca R.; Gastineau, Dennis A.; Leibovich, Bradley; Cheville, John; Kwon, Eugene D; Dietz, Allan B.

In: Clinical Cancer Research, Vol. 21, No. 18, 15.09.2015, p. 4224-4233.

Research output: Contribution to journalArticle

Gustafson, M, Lin, Y, Bleeker, JS, Warad, D, Tollefson, MK, Crispen, PL, Bulur, PA, Harrington, SM, Laborde, RR, Gastineau, DA, Leibovich, B, Cheville, J, Kwon, ED & Dietz, AB 2015, 'Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma', Clinical Cancer Research, vol. 21, no. 18, pp. 4224-4233. https://doi.org/10.1158/1078-0432.CCR-15-0260
Gustafson, Michael ; Lin, Yi ; Bleeker, Jonathan S. ; Warad, Deepti ; Tollefson, Matthew K. ; Crispen, Paul L. ; Bulur, Peggy A. ; Harrington, Susan M. ; Laborde, Rebecca R. ; Gastineau, Dennis A. ; Leibovich, Bradley ; Cheville, John ; Kwon, Eugene D ; Dietz, Allan B. / Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 18. pp. 4224-4233.
@article{de8520251f084a3c99e09ab11cc37efb,
title = "Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma",
abstract = "Purpose: Immunotherapeutic strategies to treat patients with renal cell carcinoma (RCC) offer new opportunities for disease management. Further improvements to immunotherapy will require additional understanding of the host response to RCC development. Experimental Design: Using a novel approach to understanding the immune status of cancer patients, we previously showed that patients with a certain immune profile had decreased overall survival. Here, we examine in more detail the phenotypic changes in peripheral blood and the potential consequences of these changes in RCC patients. Results: We found that CD14+HLA-DRlo/neg monocytes were the most predominant phenotypic change in peripheral blood of RCC patients, elevated nearly 5-fold above the average levels measured in healthy volunteers. Intratumoral and peritumoral presence of CD14 cells was an independent prognostic factor for decreased survival in a cohort of 375 RCC patients. The amount of peripheral blood CD14+HLA-DRlo/neg monocytes was found to correlate with the intensity ofCD14 staining in tumors, suggesting that the measurement of these cells in blood may be a suitable surrogate for monitoring patient prognosis. The interaction of monocytes and tumor cells triggers changes in both cell types with a loss of HLA-DR expression in monocytes, increases of monocyte survival factors such as GM-CSF in tumors, and increased production of angiogenic factors, including FGF2. Conclusions: Our results suggest a model ofmutually beneficial interactions between tumor cells and monocytes that adversely affect patient outcome. Clin Cancer Res; 21(18); 4224-33.",
author = "Michael Gustafson and Yi Lin and Bleeker, {Jonathan S.} and Deepti Warad and Tollefson, {Matthew K.} and Crispen, {Paul L.} and Bulur, {Peggy A.} and Harrington, {Susan M.} and Laborde, {Rebecca R.} and Gastineau, {Dennis A.} and Bradley Leibovich and John Cheville and Kwon, {Eugene D} and Dietz, {Allan B}",
year = "2015",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-15-0260",
language = "English (US)",
volume = "21",
pages = "4224--4233",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma

AU - Gustafson, Michael

AU - Lin, Yi

AU - Bleeker, Jonathan S.

AU - Warad, Deepti

AU - Tollefson, Matthew K.

AU - Crispen, Paul L.

AU - Bulur, Peggy A.

AU - Harrington, Susan M.

AU - Laborde, Rebecca R.

AU - Gastineau, Dennis A.

AU - Leibovich, Bradley

AU - Cheville, John

AU - Kwon, Eugene D

AU - Dietz, Allan B

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Purpose: Immunotherapeutic strategies to treat patients with renal cell carcinoma (RCC) offer new opportunities for disease management. Further improvements to immunotherapy will require additional understanding of the host response to RCC development. Experimental Design: Using a novel approach to understanding the immune status of cancer patients, we previously showed that patients with a certain immune profile had decreased overall survival. Here, we examine in more detail the phenotypic changes in peripheral blood and the potential consequences of these changes in RCC patients. Results: We found that CD14+HLA-DRlo/neg monocytes were the most predominant phenotypic change in peripheral blood of RCC patients, elevated nearly 5-fold above the average levels measured in healthy volunteers. Intratumoral and peritumoral presence of CD14 cells was an independent prognostic factor for decreased survival in a cohort of 375 RCC patients. The amount of peripheral blood CD14+HLA-DRlo/neg monocytes was found to correlate with the intensity ofCD14 staining in tumors, suggesting that the measurement of these cells in blood may be a suitable surrogate for monitoring patient prognosis. The interaction of monocytes and tumor cells triggers changes in both cell types with a loss of HLA-DR expression in monocytes, increases of monocyte survival factors such as GM-CSF in tumors, and increased production of angiogenic factors, including FGF2. Conclusions: Our results suggest a model ofmutually beneficial interactions between tumor cells and monocytes that adversely affect patient outcome. Clin Cancer Res; 21(18); 4224-33.

AB - Purpose: Immunotherapeutic strategies to treat patients with renal cell carcinoma (RCC) offer new opportunities for disease management. Further improvements to immunotherapy will require additional understanding of the host response to RCC development. Experimental Design: Using a novel approach to understanding the immune status of cancer patients, we previously showed that patients with a certain immune profile had decreased overall survival. Here, we examine in more detail the phenotypic changes in peripheral blood and the potential consequences of these changes in RCC patients. Results: We found that CD14+HLA-DRlo/neg monocytes were the most predominant phenotypic change in peripheral blood of RCC patients, elevated nearly 5-fold above the average levels measured in healthy volunteers. Intratumoral and peritumoral presence of CD14 cells was an independent prognostic factor for decreased survival in a cohort of 375 RCC patients. The amount of peripheral blood CD14+HLA-DRlo/neg monocytes was found to correlate with the intensity ofCD14 staining in tumors, suggesting that the measurement of these cells in blood may be a suitable surrogate for monitoring patient prognosis. The interaction of monocytes and tumor cells triggers changes in both cell types with a loss of HLA-DR expression in monocytes, increases of monocyte survival factors such as GM-CSF in tumors, and increased production of angiogenic factors, including FGF2. Conclusions: Our results suggest a model ofmutually beneficial interactions between tumor cells and monocytes that adversely affect patient outcome. Clin Cancer Res; 21(18); 4224-33.

UR - http://www.scopus.com/inward/record.url?scp=84942909842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942909842&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-0260

DO - 10.1158/1078-0432.CCR-15-0260

M3 - Article

C2 - 25999436

AN - SCOPUS:84942909842

VL - 21

SP - 4224

EP - 4233

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -